SORANIB (SORAFENIB) is an anticancer pill, a low molecular weight multikinase inhibitor that prevents cancer cells from multiplying .
SORANIB (SORAFENIB) is prescribed for patients with metastases in the kidneys, with hepatocellular and renal cell carcinoma. Additional components: microcrystalline cellulose, hydroxypropyl cellulose, hydroxypropylated cellulose.
Sorafenib destroys virtually all phosphotransferases that are located on top of infected cells. It is assumed that certain phosphotransferases are involved in the transmission of information to malignant tumors during the appearance of new blood vessels, or during the death of cancer cells. Reduces the development of tumors in hepatocellular carcinoma.
Sorafenib is recommended to be consumed under the supervision of the attending physician; the tablet should not be chewed while taking, and the effectiveness of the drug is lost.
Sorafenib is absorbed into the body within three hours after the first application. It is excreted unchanged within two weeks, 77% is excreted with feces, and 19% is excreted during urination.